Announcement PDF Atomos Limited Appendix 4E – FY26 Atomos Limited | Appendix 4E – Preliminary Final Report FY26 1 ATOMOS LTD ACN 139 730 500 ASX: AMS Appendix 4E – Preliminary Unaudited Final Report Reporting period Reporting period: for the year ended 30 June 2026 Previous corresponding period (‘PCP’): for the year ended 30 June 2025 Results for announcement to the market Atomos Ltd and its controlled entities is referred to as “Atomos”, “the Group” or “the Company” within this report. Revenue and profit/(loss) after tax for the year ended 30 June 2026: 2026 2025 % Change $'000 $'000 Revenue from ordinary activities 39,997 32,656 22.5% increase Profit/(loss) from ordinary activities after tax attributable to members 872 (14,581) 106% improvement Net profit/(loss) for the period attributable to members 872 (14,581) 106% improvement Earnings before interest, tax, depreciation and amortisation (EBITDA) 3,665 (11,833) 131% improvement Percentage changes on lines for which the previous corresponding period was a loss are calculated on the absolute value of that loss. Profit after tax improved by $15,453,000 and EBITDA by $15,498,000; the different percentages reflect the different size of the prior period losses against which each is measured. FY26 revenue increased 22.5% on the previous corresponding period. The Group returned to profit, with a net profit after tax attributable to members of $0.9m for FY26 compared with a loss of $14.6m in FY25, an improvement of $15.5m. Comparative information is presented on the basis reported in the audited financial statements for the year ended 30 June 2025. FY26 includes Flanders Scientific, Inc. from 24 April 2026. Dividends No dividends have been paid or declared during the period, and it is not proposed that any dividend be paid. No dividends were paid during the previous corresponding period. As no dividend is proposed, no record date arises and there is no amount per security or franked amount per security to report. Returns to shareholders, including distributions and buy-backs There were no returns to shareholders, including distributions or buy-backs, during the period or the previous corresponding period. Atomos Limited Appendix 4E – FY26 Atomos Limited | Appendix 4E – Preliminary Final Report FY26 2 Earnings per security and dilution Basic and diluted earnings per share are set out in the consolidated statement of profit or loss and other comprehensive income. Potential ordinary shares were on issue at 30 June 2026, including the conditional shares issuable in connection with the acquisition of Flanders Scientific, unlisted options and unvested share rights. Their dilutive effect reduces earnings per share by less than 0.01 cents, and basic and diluted earnings per share are accordingly the same when stated to two decimal places. In the previous corresponding period the potential ordinary shares were anti-dilutive because the Group recorded a loss, and basic and diluted loss per share were the same. Overview of operating results Revenue for FY26 was $40.0m, an increase of 22.5% on the previous corresponding period. Contribution margin improved to $14.9m, or 37.2% of revenue, from $5.5m, or 16.8% of revenue, reflecting improved product cost outcomes. Total fixed costs reduced by 22.5% to $12.5m, with employee benefits expense down $1.8m, advertising and marketing expense down $1.4m and legal and professional services down $1.0m following the restructuring completed in the prior year. The Group recorded EBITDA of $3.7m in FY26 compared with an EBITDA loss of $11.9m in FY25, and a net profit after tax of $0.9m in FY26 compared with a net loss of $14.6m in FY25. Finance costs increased to $2.6m from $1.4m, reflecting the higher average level of borrowings during the year. The income tax benefit of $0.6m principally reflects the recognition of a deferred tax asset against the deferred tax liability arising on the intangible assets recognised in the Flanders Scientific business combination. The reported result includes a number of individually significant items, being a net benefit of $1.4m arising on inventory which had previously been written down and the release of $0.5m of onerous contract and open purchase order provisions no longer required. Together these represent a net benefit of $1.9m, against a net charge of $1.5m in respect of the same categories in the previous corresponding period. They are set out in the Review of Operations. The result comprises a first half revenue $23.7m and EBITDA $1.9m, and a second half of revenue $16.3m and EBITDA $1.8m. The Company updated the market on second half trading on 6 July 2026. Further detail is provided in the Review of Operations and in the half-year comparison below. Annual General Meeting In accordance with ASX Listing Rule 3.13.1, the Company advises that its Annual General Meeting will be an online meeting held on 19 November 2026, and that the closing date for receipt of nominations from persons wishing to be considered for election as a director is 9 September 2026. Other details relating to the AGM will be advised in the notice of meeting to be sent to all shareholders and released to ASX immediately after dispatch. Net tangible assets per security 2026 2025 Net tangible assets per security (0.5) cents (0.9) cents Total number of shares on issue at period end 1,488,414,944 1,215,018,471 For the purposes of calculating net tangible assets per security, the carrying values of the right-of-use assets and the related lease liabilities have been excluded from the calculation, consistent with the previous corresponding period. Intangible assets are excluded from net tangible assets. On that basis net tangible assets at 30 June 2026 were negative $7.1m, being net liabilities of $2.6m less intangible assets of $4.6m less right-of-use assets of $0.8m plus lease liabilities of $0.9m. Atomos Limited Appendix 4E – FY26 Atomos Limited | Appendix 4E – Preliminary Final Report FY26 3 Entities over which control has been gained or lost during the period During the year ended 30 June 2026 the Group gained control of the following entities: Atomos SG Pte Ltd — incorporated in Singapore, control gained 14 July 2025. Issued and paid-up capital S$1. Atomos SG Pte Ltd sole activity is to provide employment services. Flanders Scientific Pty Ltd – incorporated in Australia, control gained 16 March 2026. Issued and paid-up capital $100. Flanders Scientific Pty Ltd sole activity is the ownership of Flanders Scientific, Inc. Dan Desmet & Associates, Inc., trading as Flanders Scientific, Inc. — a Georgia (United States) corporation, control gained 24 April 2026 through the acquisition of 100% of its issued share capital by Flanders Scientific Pty Ltd, a wholly-owned subsidiary of Atomos Ltd. Total consideration transferred was $2.5m. Further detail is provided in the Business combination note. Flanders Scientific, Inc. contributed revenue of $1.8m and a loss after tax of $13,000 to the consolidated result for the period from 24 April 2026 to 30 June 2026. Had the acquisition occurred on 1 July 2025, consolidated revenue would have been $49.6m and the consolidated profit after tax would have been $1.2m. No entities ceased to be controlled by the Group during the period. Associates and joint venture entities The Group had no associates or joint venture entities during the period or the previous corresponding period. Dividend reinvestment plans The Company currently does not have a dividend reinvestment plan. Independent audit report This report is based on the consolidated financial statements that are in the process of final audit completion. The independent audit report will be included within the Company’s Annual Report and an unmodified audit opinion is expected with attention drawn to material uncertainty related to going concern. As in prior years, that uncertainty arises from the Group’s net cash outflows from operating activities and its net liability position at balance date. Accounting standards This report has been compiled using Australian Accounting Standards and International Financial Reporting Standards. Other information required by Listing Rule 4.3A All other information required by Listing Rule 4.3A has been provided. Atomos Limited Appendix 4E – FY26 Atomos Limited | Appendix 4E – Preliminary Final Report FY26 4 Consolidated Statement of Profit or Loss and Other Comprehensive Income For the year ended 30 June 2026 2026 2025 $'000 $'000 Revenue 39,997 32,656 Product costs (20,372) (24,162) Variable costs (4,758) (2,998) Contribution margin 14,867 5,496 Contribution margin % 37.2% 16.8% Other income 206 - Net foreign exchange gain/(loss) 1,092 (1,191) Employee benefits expense (7,089) (8,929) Advertising and marketing expense (1,114) (2,471) Administration and other expense (1,893) (313) Legal and professional services (1,379) (2,340) Research and development expense (879) (1,579) Occupancy expense (146) (492) Transaction costs - (14) Total fixed costs (12,500) (16,138) Earnings before interest, tax, depreciation and amortisation (EBITDA) 3,665 (11,833) Finance costs (2,599) (1,426) Depreciation and amortisation (785) (1,210) Profit/(loss) before income tax 281 (14,469) Income tax benefit/(expense) 591 (112) Profit/(loss) for the year 872 (14,581) Other comprehensive income, net of income tax Items that will not be reclassified subsequently to profit or loss: - - Items that may be reclassified subsequently to profit or loss: Exchange differences on translating foreign operations (782) 1,108 Other comprehensive (loss)/income for the year (782) 1,108 Total comprehensive income/(loss) for the year 90 (13,473) Earnings per share Basic earnings/(loss) per share (cents) 0.06 (1.20) Diluted earnings/(loss) per share (cents) 0.06 (1.20) Atomos Limited Appendix 4E – FY26 Atomos Limited | Appendix 4E – Preliminary Final Report FY26 5 Consolidated Statement of Financial Position As at 30 June 2026 2026 2025 $'000 $'000 Assets Current assets Cash and cash equivalents 2,324 1,813 Trade and other receivables 6,008 1,828 Inventories 11,434 9,054 Other current assets 1,364 1,962 Total current assets 21,130 14,657 Non-current assets Property, plant and equipment 354 226 Right-of-use assets 815 1,322 Intangible assets 4,619 - Deferred tax asset 567 - Total non-current assets 6,355 1,548 Total assets 27,485 16,205 Liabilities Current liabilities Trade and other payables 5,171 6,702 Borrowings 186 181 Provisions 1,527 2,685 Lease liabilities 452 594 Income taxes payable 959 1,635 Total current liabilities 8,295 11,797 Non-current liabilities Borrowings 20,695 14,208 Provisions 82 95 Lease liabilities 478 1,196 Deferred tax liability 567 - Total non-current liabilities 21,822 15,499 Total liabilities 30,117 27,296 Net assets (2,632) (11,091) Atomos Limited Appendix 4E – FY26 Atomos Limited | Appendix 4E – Preliminary Final Report FY26 6 Equity Issued capital 142,090 134,077 Foreign currency translation reserve (319) 463 Share based payments reserve 3,948 3,627 Options reserve 264 264 Other reserves 35 - Accumulated losses (148,650) (149,522) Total equity (2,632) (11,091) Intangible assets of $4.6m comprise the intangible assets recognised on the acquisition of Flanders Scientific, capitalised product development costs and intellectual property acquired during the year. Refer to the Capitalised product development costs and Business combination notes. A reconciliation of the movement in each class of intangible asset will be included in the Annual Report. Atomos Limited Appendix 4E – FY26 Atomos Limited | Appendix 4E – Preliminary Final Report FY26 7 Consolidated Statement of Changes in Equity For the year ended 30 June 2026 FY26 movement (1 July 2025 – 30 June 2026): Issued capital Accumulated losses FX translation reserve Share- based payments reserve Options reserve Other reserves Total equity $'000 $'000 $'000 $'000 $'000 $'000 $'000 Balance at 1 July 2025 134,077 (149,522) 463 3,627 264 - (11,091) Transactions with owners Share-based payments - - - 321 - - 321 Issue of new share capital 8,013 - - - - - 8,013 Contingent consideration arising on business combination - - - - - 35 35 Total transactions with owners 8,013 - - 321 - 35 8,369 Comprehensive income Profit for the period - 872 - - - - 872 Other comprehensive loss - - (782) - - - (782) Total comprehensive income - 872 (782) - - - 90 Balance at 30 June 2026 142,090 (148,650) (319) 3,948 264 35 (2,632) FY25 movement (comparative). The closing balances below are those reported in the audited financial statements for the year ended 30 June 2025 and carry forward as the opening balances of the FY26 movement above: Atomos Limited Appendix 4E – FY26 Atomos Limited | Appendix 4E – Preliminary Final Report FY26 8 Issued capital Accumulated losses FX translation reserve Share- based payments reserve Options reserve Total equity $'000 $'000 $'000 $'000 $'000 $'000 Balance at 1 July 2024 134,037 (134,941) (645) 3,627 264 2,342 Transactions with owners Share-based payments - - - - - - Issue of new share capital 40 - - - - 40 Transaction costs relating to issue of share capital - - - - - - Total transactions with owners 40 - - - - 40 Comprehensive income Loss for the period - (14,581) - - - (14,581) Other comprehensive income - - 1,108 - - 1,108 Total comprehensive income/(loss) - (14,581) 1,108 - - (13,473) Balance at 30 June 2025 134,077 (149,522) 463 3,627 264 (11,091) Atomos Limited Appendix 4E – FY26 Atomos Limited | Appendix 4E – Preliminary Final Report FY26 9 Consolidated Statement of Cash Flows For the year ended 30 June 2026 2026 2025 $'000 $'000 Operating activities Receipts from customers 36,860 35,814 Payments to suppliers and employees (41,308) (49,061) Interest received 57 18 Income taxes paid (568) (39) Net cash used in operating activities (4,959) (13,268) Investing activities Payments for property, plant and equipment (289) (3) Payment for acquisition of subsidiary, net of cash acquired (1,860) - Payments for intellectual property (951) - Payment for capitalised development costs (1,355) - Net cash used in investing activities (4,455) (3) Financing activities Proceeds from issue of equity instruments in the company 7,878 40 Transaction costs related to issue of equity instruments (10) - Interest paid on borrowings and lease liabilities (172) (479) Repayment of lease liabilities (1,719) (695) Proceeds of borrowings 12,000 21,981 Repayment of borrowings (7,924) (8,723) Transaction costs related to loans and borrowings (121) Net cash generated by financing activities 9,932 12,124 Net change in cash and cash equivalents 518 (1,147) Cash and cash equivalents, beginning of period 1,813 2,900 Exchange differences on cash and cash equivalents (7) 60 Cash and cash equivalents, end of period 2,324 1,813 Atomos Limited Appendix 4E – FY26 Atomos Limited | Appendix 4E – Preliminary Final Report FY26 10 Notes to the Consolidated Financial Statements Amounts in the commentary in these notes are stated in millions of dollars to one decimal place, except that amounts below $0.1m are stated in dollars. Totals may not sum because of rounding. Review of Operations Revenue of $40.0m for FY26 was 22.5% above the previous corresponding period. The contribution margin of $14.9m represented 37.2% of revenue, compared with 16.8% in the prior year, reflecting lower product and freight costs following the changes to distribution arrangements made during the year. Pricing for a number of products had been increased when the US Administration’s ‘IEEPA tariffs’ were introduced and that pricing was retained after the tariffs were deemed unlawful in early 2026, which supported the margin percentage. The margin also includes the release of $1.2m of inventory obsolescence provisions and $0.5m of provisions for open purchase orders no longer required; excluding those releases the contribution margin for the year was 33.0% of revenue, within the range of 33% to 35% the Company has previously indicated. The tariffs and their reversal fell unevenly across the two halves of the year, and are discussed in the half-year comparison below. Fixed costs fell 22.5% to $12.5m. Employee benefits expense of $7.1m was $1.8m below the prior year, as was advertising and marketing expense at $1.1m, being $1.4m below FY25 and legal and professional services of $1.4m were $1.0m lower than FY25, reflecting the full-year benefit of the restructuring completed in FY25 and the reclassification of variable marketing costs to variable costs. Research and development expense of $0.9m is stated after the capitalisation of $1.4m of qualifying development expenditure from 1 January 2026 — refer to the Capitalised product development costs note. The Group recorded EBITDA of $3.7m for FY26, against an EBITDA loss of $11.9m in the prior year, and a net profit after tax of $0.9m in FY26 against a net loss of $14.6m in FY25. Finance costs of $2.6m were $1.2m higher, reflecting the higher average level of borrowings. Significant items affecting the reported result The reported result for the year includes a number of items which, by their size or nature, are relevant to an understanding of the Group’s performance. The Group does not present an underlying, normalised or adjusted result, and none of the amounts below has been excluded from any measure presented in this report. They are set out so that users can identify the items concerned together with the corresponding amounts recognised in the previous corresponding period. 2026 2025 $'000 $'000 Net benefit/(charge) — inventory obsolescence provisions and realisations 1,449 (3,184) Release of onerous contract and open purchase order provisions 450 1,714 Net benefit/(charge) recognised within EBITDA 1,899 (1,470) The net benefit of $1.4m in respect of inventory comprises the release of $1.2m of obsolescence provisions no longer required, a margin of $0.5m realised on the sale of inventory which had previously been written down, and a charge of $0.2m in respect of inventory written off against which no provision had been carried. These amounts represent the recovery of write downs recognised in FY25, when a net charge of $3.2m was made against the result, and in earlier periods; $0.8m of that recovery was realised in cash on the sale of the inventory concerned. Refer to the Movements in provision for obsolescence note. Atomos Limited Appendix 4E – FY26 Atomos Limited | Appendix 4E – Preliminary Final Report FY26 11 A provision of $0.5m carried in respect of open purchase orders was released following confirmation from the suppliers concerned that those orders had been closed and that no liability remains. The previous corresponding period included a release of $1.7m from the same onerous contract and open purchase order provisions. The release of $1.2m of obsolescence provisions and $0.5m of onerous contract and open purchase order provisions together contributed 4.2 percentage points of the contribution margin of 37.2% of revenue for the year. Excluding those releases the contribution margin was 33.0% of revenue, within the range of 33% to 35% the Company has previously indicated. Taken together, these items represent a net benefit of $1.9m in FY26 against a net charge of $1.5m in FY25. The year-on-year movement of $3.4m accounts for approximately one fifth of the $15.5m improvement in EBITDA. The balance is attributable to the 22.5% increase in revenue, the improvement in the contribution margin percentage described above following the changes to the Group’s distribution and product cost arrangements, and the $3.6m reduction in fixed costs delivered by the restructuring completed in FY25. The table above covers only those categories in which an amount arose in the current year. FY25 additionally bore employee restructuring costs of $2.7m, debt facility fees, non-recurring tradeshow costs and legal fees on historic contractual matters, disclosed as items not in the ordinary course of business in the FY25 Appendix 4E. FY26 additionally bore acquisition-related costs of $0.1m, referred to in the Business combination note, together with a number of smaller items arising in both directions, none exceeding $0.2m individually, which have not been separately identified. On 24 April 2026 the Group acquired Flanders Scientific, Inc., which contributed revenue of $1.8m and a loss after tax of $13,000 for the period from acquisition to 30 June 2026. On 14 July 2025 the Group incorporated Atomos SG Pte Ltd, whose sole activity is to provide employment services and which did not contribute revenue in the period. Half-year performance. The Group released its results for the half-year ended 31 December 2025 on 27 February 2026, reporting revenue of $23.7m, contribution margin of $8.2m or 34.7% of revenue, EBITDA of $1.9m and a profit after tax of $0.2m. Revenue and EBITDA were both within the guidance ranges previously advised to the market. At that time the Company reaffirmed its expectation that second half sales would meet or exceed the first half and that second half EBITDA would exceed the first half. On 6 July 2026 the Company advised the market that, subject to year-end audit adjustments, FY26 sales were anticipated to be in the region of $40.0m, of which approximately $16.0m would fall in the second half, against previous guidance of $23.7m for the second half. The Company attributed the shortfall to subdued end consumer demand and consequent destocking by distributors and resellers in the context of the ongoing conflict in the Middle East and rising United States inflation and interest rate expectations; approximately $2.0m of product shipped before 30 June 2026 that had not been received by customers at year end and is accordingly not recognised in FY26; the shipment of Sumo PRO 19 in the final days of May 2026, later than anticipated, which meant no re-orders were received within the financial year; and sell-through of the new Ninja range and the June promotional campaign being below expectations. The same announcement advised an expected FY26 EBITDA range of $2.5m to $3.5m. The reported result is consistent with that guidance on revenue and ahead of it on earnings. Revenue of $40.0m, of which $16.3m was earned in the second half, is in line with the 6 July 2026 announcement. EBITDA of $3.7m is $0.2m above the top of the range advised in that announcement, reflecting the improved contribution margin achieved in the second half. That margin includes the credit arising on the reversal of the ‘IEEPA tariffs’, the greater part of which relates to duties borne on first half revenues. The half-year comparison below sets out the effect. Atomos Limited Appendix 4E – FY26 Atomos Limited | Appendix 4E – Preliminary Final Report FY26 12 Summary of results for 2026 compared to prior period 2026 2025 % Change $'000 $'000 Revenue 39,997 32,656 22.5% Product costs (20,372) (24,162) (15.7%) Variable costs (4,758) (2,998) 58.7% Contribution margin 14,867 5,496 170.5% Contribution margin % 37.2% 16.8% Other income 206 - n/m Net foreign exchange gain/(loss) 1,092 (1,191) n/m Total fixed costs (12,500) (16,138) (22.5%) EBITDA 3,665 (11,833) n/m Depreciation and amortisation (785) (1,210) (35.1%) Finance costs (2,599) (1,426) 82.3% Profit/(loss) before income tax 281 (14,469) n/m Income tax benefit/(expense) 591 (112) n/m Profit/(loss) for the year 872 (14,581) n/m The presentation of the statement of profit or loss has been changed to a contribution margin format. Product costs and variable costs are presented separately, and distribution and warranty and royalty expenses previously shown as separate lines are now included within variable costs. Comparative information has been re-presented on the same basis and agrees in total to the audited financial statements for the year ended 30 June 2025. There is no effect on the reported result for either period. In the table above, n/m denotes a percentage change that is not meaningful, being lines on which the previous corresponding period was nil or on which the change in sign makes a percentage uninformative. Atomos Limited Appendix 4E – FY26 Atomos Limited | Appendix 4E – Preliminary Final Report FY26 13 Half-year comparison – H2 FY26 compared to H1 FY26 – Reported basis The half-year figures below are the reported results for the half-year ended 31 December 2025 as released to the market on 27 February 2026. The second half is derived as the difference between the full year and the first half. H2 FY26 H1 FY26 Change $ FY26 Total $'000 $'000 $'000 $'000 Revenue 16,294 23,703 (7,409) 39,997 Product costs (8,409) (11,963) 3,554 (20,372) Variable costs (1,239) (3,519) 2,280 (4,758) Contribution margin 6,646 8,221 (1,575) 14,867 Contribution margin % 40.8% 34.7% 6.1 ppt 37.2% Other income (23) 229 (252) 206 Net foreign exchange gain 1,000 92 908 1,092 Total fixed costs (5,854) (6,646) 792 (12,500) EBITDA 1,769 1,896 (127) 3,665 Depreciation and amortisation (468) (317) (151) (785) Finance costs (1,133) (1,466) 333 (2,599) Profit before income tax 168 113 55 281 Income tax benefit 553 38 515 591 Profit for the period 721 151 570 872 Second half FY26 revenue of $16.3m was $7.4m or 31.3% below the first half, for the reasons set out in the Company’s announcement of 6 July 2026. Contribution margin fell $1.6m over the same period, a smaller fall than the reduction in revenue, as the contribution margin percentage improved from 34.7% to 40.8%. Total fixed costs of $5.9m in the second half were $0.8m below the first half, reflecting the capitalisation of qualifying product development expenditure from 1 January 2026 and the reclassification of variable marketing costs, partly offset by the inclusion of Flanders Scientific from 24 April 2026. EBITDA of $1.8m was $0.1m below the first half. The movement in the contribution margin percentage between the halves is a matter of timing rather than of trading. Duties imposed by the United States Administration were borne for the whole of the first half but for only one month of the second, and the credit arising when those duties were deemed unlawful was recognised in that same month. Attributing $0.8m of that credit to the first half revenues to which it relates would give contribution margins of 38.1% in the first half and 35.9% in the second, a difference of 2.2 percentage points rather than the 6.1 percentage points reported. No adjustment has been made to the figures in the table above, which are the reported results for each half. Atomos Limited Appendix 4E – FY26 Atomos Limited | Appendix 4E – Preliminary Final Report FY26 14 Segment information The Group is managed and reported to the Board as a single operating segment. Atomos designs and sells capture, monitoring and recording products across a single production workflow — on camera, on set, and in studio and rack-mounted post-production environments. The reference-grade colour monitors acquired with Flanders Scientific sit in the studio and post-production part of that workflow, are sold to the same customer base through the same channels, and are accordingly an extension of the existing product range rather than a separate line of business. The chief operating decision maker reviews revenue, contribution margin and EBITDA for the Group as a whole in allocating resources and assessing performance, and no discrete financial information is prepared or reviewed for components below that level. No separate reportable segments therefore arise under AASB 8 Operating Segments. Inventories 2026 2025 % Change $'000 $'000 Inventories on hand at cost 16,163 17,157 Provision for obsolescence (4,729) (8,103) Inventories on hand - written down value 11,434 9,054 26.3% Inventory on hand at 30 June 2026 included $0.9m of Flanders Scientific stock as well as $0.9m attributable to sales which had been shipped prior to 30 June 2026 but not received by customers as of that date, and accordingly remained within inventory as opposed to being recognised as COGS in the P&L. Movements in provision for obsolescence Movements in the provision for inventory obsolescence during the year and the previous corresponding period were as follows: $'000 Balance at 1 July 2024 (5,622) Net charge to profit or loss (3,184) Provision utilised on inventory sold or written off 703 Balance at 30 June 2025 (8,103) Net release to profit or loss 1,217 Provision utilised on inventory sold during the year 1,496 Provision utilised on inventory written off during the year 661 Balance at 30 June 2026 (4,729) Provisions utilised during the year comprise $1.5m in respect of inventory with an original cost of $1.8m and a written down value of $0.3m, which was sold during the year for $0.8m, and $0.7m in respect of inventory with an original cost of $0.9m which was written off. The net release to profit or loss of $1.2m arises from the reassessment of the provision required at 30 June 2026 and includes $0.7m in respect of one older product line. That inventory was sold in a single transaction after the end of the financial year, which provides evidence of its net realisable value at 30 June 2026 and has accordingly been treated as an adjusting event under AASB 110 Events after the Reporting Period. Atomos Limited Appendix 4E – FY26 Atomos Limited | Appendix 4E – Preliminary Final Report FY26 15 The net effect of these movements on the result for the year was a benefit of $1.4m, comprising the release of $1.2m of provisions no longer required, a margin of $0.5m realised on the sale of inventory previously written down, and a charge of $0.2m in respect of written off inventory against which no provision had been carried. Capitalised product development costs The Group incurs expenditure on the development of new and enhanced hardware and firmware products. Expenditure on research activities is recognised as an expense in the period in which it is incurred. Development expenditure is capitalised as an intangible asset only where the Group can demonstr